Ligand Pharmaceuticals has patents filed for the manufacture and therapeutic use of certain compounds occupying several stated chemical structures, which are intended for use as selective androgen receptor modulators. The patent is filed under the following designations: US8519158 B2, US8865918, US9359285, US20070254875, US20140005186, US20150099720, and WO2005090282A1. The patents will expire on March 12, 2025. These patents effectively protect any future capitalization upon VK5211 in the market by Viking and Ligand through their licensing agreement. 
Whether you’re cutting or bulking, meeting your goals and experiencing the full potential of your Trenbolone results is certainly exciting. At this point, you will need to use some post-cycle therapy to ensure you can keep those gains. Remember that because Tren is a derivative of testosterone, it binds to the same receptors. When this happens, your body no longer produces testosterone naturally. If you simply end your cycle and fail to account for this lack of testosterone, your Trenbolone results will likely be short-lived. The symptoms of low testosterone include everything from erectile dysfunction to fat gain and even muscle loss – the exact opposite of what you worked so hard to achieve.